Kang YB, Cai Y. Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”. World J Gastroenterol 2022; 28(20): 2248-2250 [PMID: 35721889 DOI: 10.3748/wjg.v28.i20.2248]
Corresponding Author of This Article
Yong-Bo Kang, PhD, Associate Professor, Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Wenhua Street, Jinzhong 030600, Shanxi Province, China. 657151276@qq.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 28, 2022; 28(20): 2248-2250 Published online May 28, 2022. doi: 10.3748/wjg.v28.i20.2248
Future prospect of “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients”
Yong-Bo Kang, Yue Cai
Yong-Bo Kang, Yue Cai, Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Jinzhong 030600, Shanxi Province, China
Author contributions: Kang YB and Cai Y wrote the letter and conceived the manuscript; Kang YB supervised the manuscript drafting and reviewed the literature data; and all authors contributed important intellectual content during manuscript drafting or revision.
Conflict-of-interest statement: There is no conflict to declare.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yong-Bo Kang, PhD, Associate Professor, Department of Microbiology and Immunology, School of Basic Medical Sciences, Shanxi Medical University, Wenhua Street, Jinzhong 030600, Shanxi Province, China. 657151276@qq.com
Received: December 10, 2021 Peer-review started: December 10, 2021 First decision: January 8, 2022 Revised: January 14, 2021 Accepted: April 24, 2022 Article in press: April 24, 2022 Published online: May 28, 2022 Processing time: 168 Days and 4.8 Hours
Abstract
Recently, we read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that gut microbiota is closely related to therapeutic effect of nivolumab. Based on the meaningful results of this article, several valuable research directions are proposed to enhance the therapeutic effect of immune checkpoint inhibitors on advanced hepatocellular carcinoma.
Core Tip: We read the article “Gut microbiome composition can predict the response to nivolumab in advanced hepatocellular carcinoma patients” with interest, and it is preliminary suggested that the gut microbiota is closely related to therapeutic effect of nivolumab. Future research should pay attention to the relationship between the gut microbiota and therapeutic effect of immune checkpoint inhibitors (ICIs) on advanced hepatocellular carcinoma and the way of regulating the gut microbiota to improve the therapeutic effect of ICIs.
